Synthetic biology: what’s funding like now?

All funding deals in the synthetic biology market over the last 24 months

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the Synthetic Biology Market.

Is synthetic biology funding actually healthier now?

Synthetic biology funding looks healthier today, especially for companies that have already proved something, although the flow of newly funded startups has barely changed.

We counted 95 financings in the latest 12 months, up from 86 in the previous period, while the number of companies receiving funding rose from 85 to 93. At the same time, disclosed capital jumped from $1.05 billion to $1.88 billion.

The typical financing also became much larger. The median round rose from $9 million to $13.5 million, while the average climbed from $17 million to $27.2 million.

More companies are getting financed and they can raise substantially more money than they could a year earlier. The weak spot sits at the entrance to the market: the number of first-time financings has not grown.

Metric	Latest 12M	Previous 12M	Change
Deals	95	86	+10.5%
Unique funded companies	93	85	+9.4%
Disclosed capital	$1.876B	$1.052B	+78.3%
Median round	$13.5M	$9.0M	+49.9%
Average round	$27.2M	$17.0M	+60.2%
First financings	21	21	0%
Follow-on financings	73	65	+12.3%
Largest financing	$275M	$153M	+79.7%

Is the synthetic biology funding boom real without the mega-rounds?

Synthetic biology funding still looks much stronger without the mega-rounds, so the current increase goes well beyond Encoded Therapeutics' $275 million financing.

When we remove every round above $50 million, disclosed funding still rises from $589.4 million to $858 million, a 45.6% increase. Excluding rounds above $100 million leaves $1.274 billion versus $899.4 million previously, still up 41.7%.

The monthly pattern points the same way. Median monthly capital rose from $71.1 million to $117 million. The busiest recent month was unusually large, but an increase in the median means ordinary months improved too.

Even the very top of the market does not look unusually dominant. The largest financing represents 14.7% of disclosed capital, almost identical to 14.5% a year earlier.

The current boom survives a pretty aggressive stress test. The spectacular rounds help, but removing them still leaves a market raising roughly 40% to 45% more capital.

Are more synthetic biology companies getting funded, or are existing winners taking most of the money?

More synthetic biology companies are getting funded now, but existing companies are taking most of the additional dollars.

The funded population increased from 85 companies to 93. We therefore are seeing genuine breadth rather than the same tiny group recycling capital between themselves.

Still, follow-on financing explains most of the expansion. We counted 73 follow-ons versus 65 previously, and disclosed follow-on capital rose from $973.6 million to $1.739 billion.

Repeat fundraising within the same 12-month period remains rare. Matwings and MicroCyto each raised twice in the latest window, while GeneIII Biotechnology was the only company to do so in the previous one.

The market is broadening, just much more slowly than the amount of money flowing through it. Investors currently seem most willing to increase their exposure once a company has already passed an earlier funding test.

Are new synthetic biology startups still getting funded?

New synthetic biology startups are still getting funded, but the number entering the funded market has completely stalled.

We found 21 first financings in each 12-month period. Since total deal activity increased, first financings actually fell from 24.4% to 22.1% of all rounds.

The companies that do break through are getting slightly better financing. Disclosed capital going into first financings increased from $78.8 million to $122.3 million, and the median first round moved from $3.45 million to $4 million.

So there is still money available at the bottom of the market. What we are missing is an increase in the number of companies getting through the door.

For a sector currently raising far more money overall, that is probably its clearest weak point.

Are bigger synthetic biology rounds making funding more concentrated?

Bigger synthetic biology rounds are much more common today, yet the money has become less concentrated in the handful of largest deals.

The biggest change is happening further up the round-size distribution. Financings below $5 million have become much less common, while every bracket from $20 million upward has gained share.

We now count ten rounds above $50 million, versus six previously, and four rounds above $100 million instead of one.

At the same time, the top ten deals account for 54.3% of disclosed capital, down from 58.2%. The top three and top five also take slightly smaller shares than before.

Synthetic biology has therefore developed a wider group of companies capable of raising serious money. That is a healthier pattern than one giant round inflating the whole market.

Metric	Latest 12M	Previous 12M
Deals below $5M	15.8%	24.4%
$5M to under $20M	30.5%	32.6%
$20M to under $50M	13.7%	8.1%
$50M to under $100M	8.4%	5.8%
$100M+	4.2%	1.2%
Rounds above $50M	10	6
Rounds above $100M	4	1
Top 10 share of disclosed capital	54.3%	58.2%

Is synthetic biology funding moving later-stage now?

Synthetic biology funding is shifting away from Seed and toward much bigger Series A rounds, while conventional later-stage deal activity has barely changed.

Seed fell from 38.4% to 28.4% of transactions. Series A went the other way, jumping from 22.1% to 35.8%.

The difference is even stronger in dollars. Series A now absorbs 41.9% of disclosed capital, up from 25.1%, while Seed has dropped from 14.4% to 6.2%.

Meanwhile, the combined share of Series B, Series C and Series D+ deals remains close to where it was. Today's change is better understood as a move up within early-stage funding rather than a broad migration into late-stage venture rounds.

And these are not always young Series A companies. The median Series A company in our research is about 5.1 years old, versus roughly 3.9 years previously.

Stage	Deal share now	Deal share before	Capital share now	Capital share before
Seed	28.4%	38.4%	6.2%	14.4%
Series A	35.8%	22.1%	41.9%	25.1%
Series B	8.4%	8.1%	11.6%	35.0%
Series C	5.3%	4.7%	15.4%	5.3%
Series D+	2.1%	0%	17.6%	0%
Growth equity	0%	3.5%	0%	12.2%
Unknown	20.0%	23.3%	7.4%	8.0%

Do synthetic biology companies need more proof to raise money today?

Synthetic biology companies increasingly seem to need stronger clinical, manufacturing or commercial proof before investors write the biggest checks.

Company age is one clue. The median company receiving funding has moved from about 3.8 years old to 4.9 years old. Among follow-on financings, the median increased from 4.4 to 5.3 years.

The recent therapeutics rounds make the change easier to see. Encoded Therapeutics had already moved ETX101 into a pivotal study before closing its latest financing, and the new money also supports commercial-scale GMP manufacturing. BrainChild Bio closed a $116 million Series A while moving BCB-276 into a pivotal Phase 2 study.

Epicrispr gives us another useful recent example. The company reported early human clinical evidence from EPI-321 before raising its $90 million Series C. By then, the first-in-human study had progressed through dose escalation.

The same pattern appears outside therapeutics. Companies such as Tropic and EVERY are now raising around production capacity, distribution and actual commercial demand.

We cannot put a market-wide percentage on the change because milestones are not disclosed consistently enough across every financing. Still, the mix of older companies, larger Series A rounds and recent company-level evidence makes the direction fairly hard to miss.

Which synthetic biology categories have the most momentum right now?

Therapeutics and food platforms currently have the strongest synthetic biology funding momentum because both are gaining deals and attracting much larger checks.

Therapeutics has taken a particularly large step up in funding size. The category now absorbs almost half of disclosed capital, and its median financing has moved from roughly $9 million to about $46 million.

Food platforms show a different but equally convincing pattern. Their share of transactions is rising alongside capital share, and the median round has increased from $4.5 million to $16.5 million.

Biofoundry platforms are raising larger rounds despite losing some deal share. Materials and design software still produce plenty of financings, but the checks have become much smaller.

Engineered microbes are the clearest category where activity itself has weakened.

Category	Deal share now / before	Capital share now / before	Median round now / before
Synthetic biology therapeutics	18.9% / 15.1%	48.6% / 28.4%	$45.8M / $9.0M
Synbio food platforms	16.8% / 11.6%	16.5% / 6.9%	$16.5M / $4.5M
Biofoundry platforms	20.0% / 23.3%	14.1% / 12.6%	$11.0M / $5.5M
Synbio materials platforms	18.9% / 17.4%	4.3% / 14.9%	$10.3M / $18.0M
Synbio design software	10.5% / 7.0%	7.3% / 16.9%	$8.0M / $50.0M
Engineered microbes	14.7% / 25.6%	9.2% / 20.3%	$13.5M / $10.0M

Is synthetic biology therapeutics funding really broad, or is Encoded carrying the boom?

Synthetic biology therapeutics funding is broad enough to stand without Encoded, even though Encoded remains the market's largest financing.

BrainChild Bio raised $116 million around a pivotal CAR-T program. Trogenix raised $95 million to push its cancer therapies into clinical development and has since dosed the first patient in its Phase I/II TGX-007 trial.

Epicrispr raised another $90 million after producing early clinical evidence for EPI-321. Azalea Therapeutics launched with $82 million across seed and Series A financing around in vivo genome engineering. Typewriter Therapeutics has more recently emerged with a $56 million Series A focused on non-viral in vivo CAR-T medicines.

As seen above, the category's median financing is far higher than it was a year earlier. That would be impossible if one giant transaction were doing all the work.

What we are seeing currently is a cluster of well-funded therapeutic companies reaching expensive stages of development at roughly the same time.

Is synthetic biology food finally moving from the lab to commercial scale?

Synthetic biology food funding is starting to look much more like scale-up capital these days than money for another round of platform experimentation.

Tropic is a good example. The company raised $105 million after commercially launching its first new banana varieties. Tropic said demand for its non-browning and extended shelf-life bananas was already running ahead of supply, with the new capital going into large-scale plant production, supply chains and global commercial expansion.

EVERY tells a similar story in precision fermentation. Its $55 million Series D was aimed at increasing manufacturing capacity, expanding distribution and moving toward profitability as products using its proteins entered nationwide retail.

The follow-up is even more interesting than the funding announcement. EVERY later said its expanded manufacturing agreement with Huvepharma would quadruple production capacity. The company also reported that orders secured during the first four months of 2026 were worth 550% of its entire 2025 order volume.

That is the kind of operating evidence we want to see behind larger food-synbio rounds. Investors are increasingly paying for capacity because companies have something to produce and customers to serve.

Where is synthetic biology funding actually getting weaker?

Engineered microbes are where synthetic biology funding has weakened most clearly, while materials and design software mainly suffer from smaller checks.

Engineered microbes fell from 25.6% to 14.7% of deals. Their share of disclosed capital also dropped from 20.3% to 9.2%.

Materials look different. Their deal share actually increased slightly, from 17.4% to 18.9%, while capital share fell sharply from 14.9% to 4.3%. The median round also dropped from $18 million to $10.3 million.

Design software shows a similar split between activity and financing size. Deal share rose from 7% to 10.5%, but capital share fell from 16.9% to 7.3%. The previous period was helped by unusually large rounds from companies such as Cradle and Basecamp Research.

Engineered microbes have genuinely lost breadth. Materials and design software are still attracting startups and investors, just with less money attached to each deal.

Is the US taking synthetic biology funding away from Europe?

The US is taking a much larger share of synthetic biology capital now, while Europe's decline is far more dramatic in dollars than in the number of deals.

North America increased from 23.3% to 27.4% of transactions, but its share of disclosed capital jumped from 36% to 57.2%. The US alone went from 18 to 24 deals and now captures 56.6% of known funding.

Europe's deal share fell from 33.7% to 27.4%. More strikingly, its capital share dropped from 49.4% to 28.1%.

Asia-Pacific has been much steadier. It still represents 40% of deals, and China actually increased from 29 financings to 33.

The current geographic shift therefore looks more like a US round-size boom combined with weaker European funding than a wholesale movement of synthetic biology activity from Asia to North America.

Are corporate investors becoming more important in synthetic biology?

Corporate investors are showing up much more often in synthetic biology rounds today, while the wider disclosed investor pool also appears to be growing.

We found strategic investors in 28 financings, up from 13. That takes the strategic participation rate from 15.1% to 29.5%.

Interestingly, the median strategic-backed round fell from $16.5 million to $12.7 million. Corporates appear across more ordinary financings now rather than concentrating only on the blockbuster deals.

The examples span several parts of the market. Corteva co-led Tropic's Series C through Corteva Catalyst. Eli Lilly participated in Trogenix's Series A. Sanofi Ventures joined Epicrispr's latest financing.

Profluent offers another kind of strategic validation. The company later signed an agreement with Eli Lilly to develop AI-designed recombinases for genetic medicine, with the broader deal reported as potentially worth up to $2.25 billion.

Our investor records also contain 128 unique disclosed investor entities versus 90 previously, while investors appearing in more than one financing increased from six to 17. We should be a little more careful with those figures because investor disclosure itself improved from 74.4% to 86.3% of deals. Even with that caveat, we see no sign that the investor pool is narrowing.

Are synthetic biology companies raising again faster now?

Synthetic biology companies do not appear to be returning for follow-on funding faster, at least from the round histories we can verify.

For follow-ons with a usable previous financing date, the median gap increased from 13.7 months to 15.7 months. Only 17.6% of the latest sample returned within 12 months, compared with 40% previously.

This is one place where we should keep the conclusion modest. Previous-round dates are available for only 17 current follow-ons and five in the earlier period. Five historical observations are too few to argue that fundraising cycles have genuinely slowed.

Still, the available evidence gives us no reason to say that today's stronger funding market is letting companies come back for money faster.

What is the most misleading headline about synthetic biology funding today?

The most misleading synthetic biology funding headline today would simply be "funding is up 78%," because the bigger story is who can raise that money and what they are raising it for.

The headline increase is real. It survives the removal of mega-rounds, more companies are receiving capital, and bigger financings now appear across a wider group of businesses.

Yet new-company formation has gone nowhere. Seed has lost a large chunk of deal share. The average funded company is older. Follow-ons dominate the additional dollars.

At the same time, recent financing announcements increasingly talk about pivotal trials, manufacturing capacity, product supply and commercial expansion.

Put together, synthetic biology currently looks less like a fresh startup boom and more like a market where a larger cohort of surviving companies is reaching expensive stages of development.

What really changed over the last 12 months?

Synthetic biology has become a stronger funding market, although the improvement is heavily tilted toward companies that already have a financing history. Deal breadth is up, typical rounds are larger and the increase remains strong after removing the biggest transactions.

The market has also moved noticeably up the financing curve. Small rounds have lost ground while $20 million-plus financings have become much more common. Even with more large rounds, the top few companies take a smaller share of total capital than before.

The entry point remains the clearest weakness. The number of first financings has not increased even as the overall market expanded, so today's extra capital is doing more to push existing companies forward than to create a larger generation of newly funded startups.

Series A now sits at the center of the market. These rounds are often financing companies that have already spent four or five years developing technology, building clinical programs or proving commercial demand, which makes a simple "early-stage versus late-stage" split much less useful.

Therapeutics and food platforms have the most convincing momentum. Therapeutics combines broader deal activity with several large clinical-stage financings, while food companies such as Tropic and EVERY now provide concrete evidence of manufacturing and commercial scale-up behind their recent rounds.

Investor behavior has changed too. Strategic participation has become much more common, and large pharmaceutical and agricultural companies are appearing around technologies that have moved beyond basic scientific promise.

The simplest way to describe synthetic biology today is a market that has become better funded, broader at the company level and considerably more mature, while still struggling to expand the pipeline of first-time funded startups.